Enterprise Value
42.01M
Cash
52.88M
Avg Qtr Burn
-3.072M
Short % of Float
0.73%
Insider Ownership
2.98%
Institutional Own.
22.60%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MN-166 (ibudilast) Details Neurological disorder, Degenerative Cervical Myelopathy | Phase 2/3 Data readout | |
MN-166 (ibudilast) Details Amyotrophic lateral sclerosis, Neurodegenerative disease | Phase 2/3 Data readout | |
MN-166 (ibudilast) Details Neuropathy, Neurological disorder | Phase 2b Data readout | |
MN-166 (ibudilast) Details Alcohol dependence | Phase 2b Update | |
MN-001 (tipelukast) Details Non-alcoholic steatohepatitis , Liver disease | Phase 2 Interim update | |
MN-166 (ibudilast) Details Glioblastoma, Cancer | Phase 2 Update | |
MN-166 (ibudilast) Details COVID-19 | Phase 2 Update | |
MN-166 (ibudilast) Details Multiple sclerosis, Central nervous system illness | Phase 2 Update | |
MN-001 (tipelukast) Details Interstitial lung disease, Lung disease, Idiopathic pulmonary fibrosis | Phase 2 Update | |
SAR444836 Details Phenylketonuria | Phase 1/2 Data readout |